Related Experiment Videos
Case study: risperidone in children and adolescents with schizophrenia
1University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, PA, USA.
Summary
Risperidone, a novel neuroleptic, showed significant improvement in negative symptoms for adolescent schizophrenia patients. This study suggests potential effectiveness for treating pediatric schizophrenia with this 5-HT2/D2 receptor antagonist.
Area of Science:
- Child and Adolescent Psychiatry
- Neuropharmacology
- Mental Health Research
Background:
- Schizophrenia in children is rare but severe, necessitating research into effective treatments.
- Limited studies exist on novel neuroleptics for pediatric schizophrenia, particularly concerning positive and negative symptoms.
Observation:
- Four adolescent patients (12-17 years) diagnosed with schizophrenia participated in the study.
- Treatment involved risperidone, a 5-HT2/D2 receptor blocking agent, at a dosage of 4 to 5 mg/day.
Findings:
- Three out of four patients experienced substantial improvement in negative symptoms.
- No significant side effects were reported during the treatment period.
Implications:
- Risperidone demonstrates potential efficacy in treating negative symptoms of schizophrenia in adolescents.
- Further research is warranted to confirm these findings and explore long-term outcomes in pediatric populations.